Reciprocal t (9;22) ABL/BCR fusion proteins: Leukemogenic potential and effects on B cell commitment

PLoS ONE

Volumn 4, Issue 10, 2009, Pages

  Zheng, Xiaomin ^a,b   Oancea, Claudia ^a   Henschler, Reinhard ^a   Moore, Malcolm A S ^b   Ruthardt, Martin ^a  

^a GOETHE UNIVERSITY   (Germany)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; PROTEIN P185; PROTEIN P40;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE; CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMOSOME 22; COLONY FORMING CELL; CONTROLLED STUDY; HEMATOPOIETIC STEM CELL; MOUSE; MYELOID PROGENITOR CELL; NONHUMAN; PRE B LYMPHOCYTE; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; RECIPROCAL CHROMOSOME TRANSLOCATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UMBILICAL CORD BLOOD; ANIMAL; CELL STRAIN U937; CHROMOSOME 9; CHRONIC MYELOID LEUKEMIA; CYTOLOGY; FETUS BLOOD; GENE TRANSLOCATION; GENETICS; HUMAN; RETROVIRUS; STEM CELL;

MURINAE;

ANIMALS; B-LYMPHOCYTES; CELL DIFFERENTIATION; CHROMOSOMES, HUMAN, PAIR 22; CHROMOSOMES, HUMAN, PAIR 9; FETAL BLOOD; FUSION PROTEINS, BCR-ABL; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; RETROVIRIDAE; STEM CELLS; TRANSLOCATION, GENETIC; U937 CELLS;

EID: 70449382606     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0007661     Document Type: Article

References (45)

1. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, et al. (1999) The biology of chronic myeloid leukemia. N Engl J Med 341: 164-172.
2. Melo JV, Barnes DJ (2007) Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 7: 441-453.
3. Radich JP (2007) The Biology of CML Blast Crisis. Hematology Am Soc Hematol Educ Program. pp 384-391.
4. Gökbuget N, Hoelzer D (2006) Treatment of adult acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. pp 133-141.
5. Barnes DJ, Melo JV (2002) Cytogenetic and molecular genetic aspects of chronic myeloid leukaemia. Acta Haematol 108: 180-202.
6. Melo JV, Gordon DE, Cross NC, Goldman JM (1993) The ABL-BCR fusion gene is expressed in chronic myeloid leukemia. Blood 81: 158-165.
7. Melo JV, Gordon DE, Tuszynski A, Dhut S, Young BD, et al. (1993) Expression of the ABL-BCR fusion gene in Philadelphia-positive acute lymphoblastic leukemia. Blood 81: 2488-2491.
8. Barnes DJ,Melo JV (2006) Primitive, quiescent and difficult to kill: the role of non-proliferating stem cells in chronic myeloid leukemia. Cell Cycle 5: 2862-2866.
9. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, et al. (2006) Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354: 2542-2551.
10. Tokarski J, Newitt J, Chang CYJ, Cheng J, Wittekind M, et al. (2006) The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 66: 5790-5797.
11. Zheng X, Güller S, Beissert T, Puccetti E, Ruthardt M (2006) BCR and its mutants, the reciprocal t(9;22)-associated ABL/BCR fusion proteins, differentially regulate the cytoskeleton and cell motility. BMC Cancer 6: 262.
12. Radziwill G, Erdmann RA, Margelisch U, Moelling K (2003) The Bcr kinase down-regulates Ras signaling by phosphorylating AF-6 and binding to its PDZ domain. Mol Cell Biol 23: 4663-4672.
13. Ress A, Moelling K (2006) Bcr interferes with beta-catenin-Tcf1 interaction. FEBS Lett 580: 1227-1230.
14. Aelst LV, D'Souza-Schorey C (1997) Rho GTPases and signaling networks. Genes Dev 11: 2295-2322.
15. Whitehead I, Campbell S, Rossman KL, Der CJ (1997) Dbl family proteins. Biochim Biophys Acta 1332: F1-23.
16. Zheng X, Beissert T, Kukoc-Zivojnov N, Puccetti E, Altschmied, et al. (2004) Gamma-catenin contributes to leukemogenesis induced by AML-associated translocation products by increasing the self-renewal of very primitive progenitor cells. Blood 103: 3535-3543.
17. Lavau C, Szilvassy SJ, Slany R, Cleary ML (1997) Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL. EMBO J 16: 4226-4237.
18. Johnson JJ, Chen W, Hudson W, Yao Q, Taylor M, et al. (2003) Prenatal and postnatal myeloid cells demonstrate stepwise progression in the pathogenesis of MLL fusion gene leukemia. Blood 101: 3229-3235.
19. Orkin SH, Zon LI (2008) Hematopoiesis: an evolving paradigm for stem cell biology. Cell 132: 631-644.
20. Puccetti E, Ruthardt M (2004) Acute promyelocytic leukemia: PML/RARalpha and the leukemic stem cell. Leukemia 18: 1169-1175.
21. Kogan SC, Ward JM, Anver MR, Berman JJ, Brayton C, et al. (2002) Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood 100: 238-245.
22. Feldhahn N, Henke N, Melchior K, Duy C, Soh BN, et al. (2007) Activation-induced cytidine deaminase acts as a mutator in BCR-ABL1-transformed acute lymphoblastic leukemia cells. J Exp Med 204: 1157-1166.
23. Ohkawara JI, Ikebuchi K, Fujihara M, Sato N, Hirayama F, et al. (1998) Culture system for extensive production of CD19+IgM+ cells by human cord blood CD34+ progenitors. Leukemia 12: 764-771.
24. Cobaleda C, Schebesta A, Delogu A, Busslinger M (2007) Pax5: the guardian of B cell identity and function. Nat Immunol 8: 463-470.
25. Hagman J, Lukin K (2006) Transcription factors drive B cell development. Curr Opin Immunol 18: 127-134.
26. Gonda H, Sugai M, Nambu Y, Katakai T, Agata Y, et al. (2003) The balance between Pax5 and Id2 activities is the key to AID gene expression. J Exp Med 198: 1427-1437.
27. Mathas S, Janz M, Hummel F, Hummel M, Wollert-Wulf B, et al. (2006) Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma. Nat Immunol 7: 207-215.
28. Jumaa H, Hendriks RW, Reth MB (2005) Cell signaling and tumorigenesis. Annu Rev Immunol 23: 415-445.
29. Fu C, Turck CW, Kurosaki T, Chan, AC (1998) BLNK: a central linker protein in B cell activation. Immunity 9: 93-103.
30. Michor F, Iwasa Y, Nowak MA (2006) The age incidence of chronic myeloid leukemia can be explained by a one-mutation model. Proc Natl Acad Sci U S A 103: 14931-14934.
31. Era T, Witte ON (2000) Regulated expression of P210 Bcr-Abl during embryonic stem cell differentiation stimulates multipotential progenitor expansion and myeloid cell fate. Proc Natl Acad Sci U S A 97: 1737-1742.
32. Huntly BJP, Shigematsu H, Deguchi K, Lee BH, Mizuno S, et al. (2004) MOZ-TIF2, but not BCR-ABL confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 6: 587-596.
33. Wilson A, Murphy MJ, Oskarsson T, Kaloulis K, Bettess MD, et al. (2004) c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation. Genes Dev 18: 2747-2763.
34. Alberts AS, Treisman R (1998) Activation of RhoA and SAPK/JNK signalling pathways by the RhoA-specific exchange factor mNET1. EMBO J 17: 4075-4085.
35. Griswold IJ, MacPartlin M, Bumm T, Goss VL, O'Hare T, et al. (2006) Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol Cell Biol 26: 6082-6093.
36. Beissert T, Hundertmark A, Kaburova V, Travaglini L, Mian, AA, et al. (2008) Targeting of the N-terminal coiled coil oligomerization interface by a helix-2 peptide inhibits unmutated and imatinib-resistant BCR/ABL. Int J Cancer 122: 2744-2752.
37. Yin JL, Williams BG, Arthur CK, Ma DD (1995) Interferon response in chronic myeloid leukaemia correlates with ABL/BCR expression: a preliminary study. Br J Haematol 89: 539-545.
38. Huntly BJ, Reid AG, Bench AJ, Campbell LJ, Telford N, et al. (2001) Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood 98: 1732-1738.
39. de la Fuente J, Merx K, Steer EJ, Müller M, Szydlo RM, et al. (2001) ABL-BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemia. Blood 98: 2879-2880.
40. Kreil S, Pfirrmann M, Haferlach C, Waghorn K, Chase A, et al. (2007) Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia. Blood 110: 1283-1290.
41. Klein F, Feldhahn N, Harder L, Wang H, Wartenberg M, et al. (2004) The BCR-ABL1 kinase bypasses selection for the expression of a pre-B cell receptor in pre-B acute lymphoblastic leukemia cells. J Exp Med 199: 673-685.
42. Heisterkamp N, Jenster G, ten Hoeve J, Zovich D, Pattengale PK, et al. (1990) Acute leukaemia in bcr/abl transgenic mice. Nature 344: 251-253.
43. Huettner CS, Zhang P, Etten RAV, Tenen DG (2000) Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet 24: 57-60.
44. Etten RAV (2002) Studying the pathogenesis of BCR-ABL+ leukemia in mice. Oncogene 21: 8643-8651.
45. Bug G, Gül H, Schwarz K, Pfeifer H, Kampfmann M, et al. (2005) Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells. Cancer Res 65: 2537-2541.